HCLC Stock Overview
Health-Chem Corporation, through its subsidiary, Transderm Laboratories Corporation, engages in the research, development, manufacture, and marketing of transdermal drug delivery systems in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Health-Chem Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | -99.50% |
| 5 Year Change | -96.67% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| HCLC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -3.2% |
| 1Y | 0% | -3.7% | 19.3% |
Return vs Industry: HCLC underperformed the US Medical Equipment industry which returned 14% over the past year.
Return vs Market: HCLC underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| HCLC volatility | |
|---|---|
| HCLC Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HCLC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HCLC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | n/a | Ronald Burghauser | n/a |
Health-Chem Corporation, through its subsidiary, Transderm Laboratories Corporation, engages in the research, development, manufacture, and marketing of transdermal drug delivery systems in the United States. It offers transdermal nitroglycerin patches used for transdermal relief of the vascular and cardiovascular symptoms related to angina pectoris (chest pain). The company also conducts research and development activities for third parties on a contract basis.
Health-Chem Corporation Fundamentals Summary
| HCLC fundamental statistics | |
|---|---|
| Market cap | US$1.23k |
| Earnings (TTM) | -US$837.00k |
| Revenue (TTM) | US$5.28m |
0.0x
P/S Ratio0.0x
P/E RatioIs HCLC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCLC income statement (TTM) | |
|---|---|
| Revenue | US$5.28m |
| Cost of Revenue | US$5.88m |
| Gross Profit | -US$600.00k |
| Other Expenses | US$237.00k |
| Earnings | -US$837.00k |
Last Reported Earnings
Jun 30, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did HCLC perform over the long term?
See historical performance and comparison